Download PDF
Arzneimittelforschung 2009; 59(7): 370-376
DOI: 10.1055/s-0031-1296410
Antibiotics · Antimycotics · Antiparasitics · Antiviral Drugs · Chemotherapeutics · Cytostatics
Editio Cantor Verlag Aulendorf (Germany)

Bioavailability of a Co-formulated Combination of Amodiaquine and Artesunate under Fed and Fasted Conditions

Serge Fitoussi
1   Mediscis, Lagord, France
,
Carole Thang
1   Mediscis, Lagord, France
,
Eric Lesauvage
1   Mediscis, Lagord, France
,
Jérôme Barré
2   Centre Hospitalier Intercommunal, Créteil, France
,
Brigitte Charron
3   Sanofi-Aventis, Paris, France
,
Aziz Filali-Ansary
3   Sanofi-Aventis, Paris, France
,
Valérie Lameyre
3   Sanofi-Aventis, Paris, France
› Author Affiliations
Further Information

Publication History

Publication Date:
13 December 2011 (online)

    Permissions and Reprints

Abstract

Objectives:

To assess the effect of food on the pharmacokinetics of the anti-malarial amodiaquine (AQ, CAS 6398-98-7) and artesunate (AS, CAS 182824-33-5) and their active metabolites [desethylamodia-quine (DSA][CAS 81496-81-3) and dihy-droartemisinin (DHA][CAS79352-78-6)][respectively] in healthy volunteers.

Methods:

In an open, two-way crossover study, 22 healthy male volunteers fasted overnight and were randomised to receive a single oral administration of 4 tablets of a fixed-dose combination containing 135 mg AQ and 50 mg AS in the absence or presence of a standardised high-fat breakfast, administered 30 min before drug administration. Blood samples were collected up to Day 10 and AQ, DSA, AS and DHA were assayed by an LC/MS/MS method.

Results:

Relative to the fasting state, the administration of the fixed-dose combination after a high-fat breakfast resulted in delayed median Tmax values for AQ (15 min and for DSA (2.3 h). The geometric mean ratios (GMR) of fed to fasting conditions indicated increased Cmax values for AQ (GMR 1.22) (90% CI: 1.07–1.39) and DSA (GMR 1.21) (90% CI: 1.05–1.39) and increased AUC0–t values for AQ (GMR 1.59) (90% CI: 1.39–1.83) and for DSA (GMR 1.13) (90% CI: 1.04–1.24). The median Tmax values were not delayed for AS as opposed to DHA (approximately 1 h delay). The Cmax values were decreased for AS (GMR 0.36) (90% CI: 0.30–0.47) and for DHA (GMR 0.51) (90% CI: 0.44–0.60). The AUC0–t values were slightly decreased for AS (GMR 0.89) (90% CI: 0.74–1.06) and for DHA (GMR 0.93) (90% CI: 0.84–1.02).

Conclusion:

Intake of AQ and AS with a high fat meal resulted in (1) a statistically significant increase in blood levels of AQ and DSA which may affect the safety and tolerability of the study drugs and (2) a decrease in AS and DHA blood levels which may affect efficacy. These results suggest that the fixed-dose combination should not be administered with a high-fat meal.

Key words

Amodiaquine - Artesunate - CAS 6398-98-7 - CAS 182824-33-5 - Coarsucam™ - Fixed-dose anti-malarial combination, food effect, pharmacokinetics
 

  • References

  • 1 Olumese P et al. WHO Guidelines for the treatment of Malaria. Geneva: WHO Library Cataloguing-in-Publication Data; 2006
    Google Scholar
  • 2 Menard D, Andrianina NN, Ramiandrasoa Z, Randriamanantena A, Rasoarilalao N, Jahevitra M et al. Randomized clinical trial of artemisinin versus non-artemisinin combination therapy for uncomplicated falciparum malaria in Madagascar. Malar J. 2007; 6: 65
    CrossrefPubMedGoogle Scholar
  • 3 Nosten F, White NJ. Artemisinin-based combination treatment of falciparum malaria. Am J Trop Med Hyg. 2007; 77: 181-92
    PubMedGoogle Scholar
  • 4 Adjuik M, Agnamey P, Babiker A, Borrmann S, Brasseur P, Cisse M et al. Amodiaquine-artesunate versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children: a randomised, multicentre trial. Lancet. 2002; 359: 1365-72
    CrossrefPubMedGoogle Scholar
  • 5 White NJ. Delaying antimalarial drug resistance with combination chemotherapy. Parasitologia. 1999; 41: 301-8
    PubMedGoogle Scholar
  • 6 Luo XD, Shen CC. The chemistry, pharmacology, and clinical applications of qinghaosu (artemisinin) and its derivatives. Med Res Rev. 1987; 7: 29-52
    CrossrefPubMedGoogle Scholar
  • 7 Krishna S, White NJ. Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications. Clin Pharmacokinet. 1996; 30: 263-99
    CrossrefPubMedGoogle Scholar
  • 8 Sirima SB, Gansane A. Artesunate-amodiaquine for the treatment of uncomplicated malaria. Expert Opin Investig Drugs. 2007; 16: 1079-85
    CrossrefPubMedGoogle Scholar
  • 9 Dien TK, de Vries PJ, Khanh NX, Koopmans R, Binh LN, Duc DD et al. Effect of food intake on pharmacokinetics of oral artemisinin in healthy Vietnamese subjects. Antimicrob Agents Chemother. 1997; 41: 1069-72
    PubMedGoogle Scholar
  • 10 Davis TM, Karunajeewa HA, Ilett KF. Artemisinin-based combination therapies for uncomplicated malaria. Med J Aust. 2005; 182: 181-5
    PubMedGoogle Scholar
  • 11 Ezzet F, van Vugt M, Nosten F, Looareesuwan S, White NJ. Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. Antimicrob Agents Chemother. 2000; 44: 697-704
    CrossrefPubMedGoogle Scholar
  • 12 Ashley EA, Stepniewska K, Lindegardh N, Annerberg A, Kham A, Brockman A et al. How much fat is necessary to optimize lumefantrine oral bioavailability? Trop Med Int Health. 2007; 12: 195-200
    PubMed
  • 13 Hietala SF, Bhattarai A, Msellem M, Roshammar D, Ali AS, Stromberg J et al. Population pharmacokinetics of amodiaquine and desethylamodiaquine in pediatric patients with uncomplicated falciparum malaria. J Pharmacokinet Pharmacodyn. 2007; 34: 669-86
    CrossrefPubMedGoogle Scholar